Adjuvant Discovery, Validation, and Advancement through Novel Candidate Evaluation (ADVANCE) BAA-DAIT-75N930##R#####
Forecast New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $100,000,000 or more
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Zachary Fetters zachary.fetters@nih.gov (240) 236-9291
- Wolfgang Leitner wleitner@niaid.nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health (NIH) is forecasting a new requirement for the Adjuvant Discovery, Validation, and Advancement through Novel Candidate Evaluation (ADVANCE) broad agency announcement (BAA) contract solicitation, with an estimated solicitation release date of December 1, 2026. The contracts will support discovery, systematic down-selection, and/or development of vaccine adjuvants for vaccines that prevent or treat human disease caused by infectious pathogens, and for therapeutics that treat immune-mediated diseases such as allergic and autoimmune diseases. The program spans adjuvant discovery, optimization, and selection through current Good Manufacturing Practice (cGMP) manufacturing and Investigational New Drug (IND) enabling studies, with an estimated award date of March 1, 2028, and no set-aside.
The estimated minimum award value is $100 million under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Points of contact are Zachary Fetters, Contracting Officer, National Institutes of Health (zachary.fetters@nih.gov, +1 240-236-9291), and Wolfgang Leitner, Chief, Innate Immunity Section, National Institutes of Health (wleitner@niaid.nih.gov).
Forecast text
This request is for review and approval of a BAA contract solicitation to support the discovery and development of vaccine adjuvants. A vaccine adjuvant is an agent that is formulated with a vaccine product with the purpose of potentiating or modulating the specific immune response to the antigen. The contracts will support the discovery, systematic down-selection, and/or development of adjuvants for use in vaccines to prevent or treat human disease caused by infectious pathogens or to treat immune-mediated diseases (e.g., allergic diseases, autoimmune diseases). The initiative is designed to effectively support the spectrum of product development activities in one seamless program from adjuvant discovery, optimization, and selection, through current Good Manufacturing Practice (cGMP) manufacturing and Investigational New Drug (IND) enabling studies. The solicitation is important as there is increased demand for adjuvants as protein subunit vaccines require an adjuvant for efficacy and the National Institute of Allergy and Infectious Diseases (NIAID) has a long standing interest in the development of adjuvants to replace aluminum, which is currently the predominant adjuvant in licensed, adjuvanted vaccines. This program also develops adjuvants for use as therapeutics for the treatment of allergic and immune-mediated diseases.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast